Related Experiment Video
Updated: Apr 21, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.9K
Are you ready for more insulin concentrations?
Alissa R Segal1, Nuha El Sayed2
1MCPHS University, Boston, MA, USA Joslin Diabetes Center, Boston, MA, USA alissa.segal@mcphs.edu.
Journal of Diabetes Science and Technology
|November 12, 2014
Summary
New concentrated insulins are emerging, offering potential solutions to challenges posed by current high-concentration insulin products like U500R. This review examines these new options for improved patient and provider experiences.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Management
Background:
- Current insulin therapy options are limited, with only two concentrations (100 units/mL and 500 units/mL) available.
- These limitations present significant challenges for both patients and healthcare providers in managing diabetes effectively.
Purpose of the Study:
- To review and summarize available information on newly developed concentrated insulin products.
- To provide a comparative analysis with existing concentrated insulin, regular insulin 500 units/mL (U500R).
Main Methods:
- Information was gathered from various sources including publications, poster presentations, abstracts, and direct manufacturer data.
- Analysis focused on the activity profiles and usage challenges of U500R as a benchmark.
Main Results:
- New concentrated insulin formulations are in development, with varying stages of availability.
- These newer products aim to address the difficulties associated with using U500R.
Conclusions:
- The upcoming expansion of concentrated insulins requires practitioner preparedness.
- Newer formulations may offer improved solutions for clinicians and patients compared to current U500R.
Related Concept Videos
01:26Hypoglycemia
3
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
3
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:27Insulin Formulations: Types and Delivery
1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.2K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
3.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
3.3K
01:16Hormones Regulating Blood Glucose
9.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
9.1K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
2.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.2K